VC Deals Analysis: Positive Exit Markets Keep Venture Investment Swell Growing
Executive Summary
Big-buck rounds of over $100m seem to be becoming the standard – rather than one-offs – in the medtech venture financing scene, with yet another two of these nine-figure transactions recorded in April. These mega rounds, together with the healthy deal volume seen that month, boosted total deal value to nearly $700m.
You may also be interested in...
BioTrinity 2018: Bullish M&A And IPO Outlook; Spotlight On Eyevensys, Rexgenero
Industry experts, investors and start-ups from across the pharma, biotech and medtech sectors gathered at the recent annual BioTrinity conference held in London to hear how the capital-raising climate is looking rosy for 2018, and to explore partnering and investment opportunities. Medtech Insight reports on predicted trends in health care and highlights two companies, Eyevensys and Rexgenero, that were presenting at the conference.
VC Deals Analysis: Best Q1 Yet With Unrelenting Bull Run
The pace of medtech venture financing activity did not slacken in March, as the month welcomed yet another batch of big financing rounds, making it the most prolific first-quarter in the last three years for fundraisings of $100m-and-over.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.